<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
<th>Objectives</th>
</tr>
</thead>
</table>
| 9:00    | Psychopharmacology Myths or Facts          | Tawny Smith, Pharm.D., BCPP. (Associate Professor of Psychiatry) Marisa S. P. Toups, M.D. (Assistant Professor of Psychiatry) The University of Texas at Austin Dell Medical School | - Examine common practices for addressing side effect management of psychotropics  
- Evaluate the evidence for treatment interventions for side effect management  
- Determine if common clinical approaches to side effect management are evidence based |
| 10:15   | Psychotropic New Drug Update               | Stephen R. Saklad, Pharm.D., BCPP (Clinical Associate Professor)             | - Describe the pharmacology, adverse effects, drug interactions, therapeutic uses, and dosing of selected psychiatric drugs recently marketed as well as drugs approaching the market.  
- Review pharmacology, adverse effects, drug interactions, therapeutic uses, and dosing of selected psychiatric drugs that have been released in the past five years. |
| 11:30   | Dietary and Natural Treatments for Mental Health Disorders: Fact vs. Fiction | Marisa S. P. Toups, M.D. (Assistant Professor of Psychiatry) The University of Texas at Austin Dell Medical School | - Describe the relationship of diet and nutrition to mental health status  
- Catalog the use of complementary & alternative medications (CAM) and dietary approaches in the treatment of psychiatric disorders using literature-supported evidence.  
- Evaluate safety concerns regarding CAM and dietary adverse effects and drug interactions with common natural and herbal remedies used to treat psychiatric disorders. |
| 1:00    | Trauma-Informed Care                       | Valerie Rosen, M.D. (Associate Professor) Department of Psychiatry The University of Texas at Austin Dell School of Medicine | - Summarize the core components of trauma-informed care  
- Discuss and analyze the role of healthcare providers in trauma-informed care  
- Develop a trauma-informed care plan based on best practices |
| 2:15    | Clozapine Update and Management of Side Effects | Rania Kattura, Pharm.D., MSPhr, BCPP (Clinical Psychiatric Pharmacist) Austin State Hospital | - Review Clozapine monitoring guidelines, its initiation, titration and maintenance  
- Discuss utility of clozapine in serious mental illness and barriers for its use  
- Identify successful strategies for successful clozapine use  
- Detail common and uncommon clozapine induced side effects and their management |
| 3:30    | Role of Pharmacologic Agents in Personality Disorders | Samantha Vogel, Pharm.D., BCPP (Clinical Assistant Professor for Pharmacy Practice) The University of Texas at Austin College of Pharmacy | - Review key signs and symptoms of personality clusters and individual disorders  
- Discuss the efficacy of pharmacologic treatment in the management of personality disorders  
- Apply evidence-based treatment options using a case example |
| 4:45    | Oral Injectable Treatments for Schizophrenia: A Case Study Discussion | Stephen R. Saklad, Pharm.D., BCPP (Clinical Associate Professor) Brendan Hogan, PharmD, BCPP (Clinical Pharmacy Manager) Mental Health and Pain Central Texas Veterans Health Care System | - Examine currently available oral and long-acting injectable (LAI) antipsychotics for the treatment of schizophrenia  
- Critique patient case’s use of LAIs including agent selection, initiation regimen, dosing, monitoring, and crises |
ON-Demand Sessions • Released October 13th

The Management of Treatment Resistant Depression: The Art and Science
Charles Nemeroff, M.D., Ph.D.
Chair and Professor
Department of Psychiatry
The University of Texas at Austin Dell School of Medicine
- Explain the latest treatment advances and research findings for treatment-resistant depression (TRD)
- Describe the emerging strategies in the use of atypical antipsychotics and new agents in the treatment of TRD
- Demonstrate the integration of appropriate psychopharmacologic treatments into a comprehensive treatment plan, including cognitive and behavioral psychotherapies
- Discuss the evidence for the following agents in the management of TRD: Ketamine, rTMS, ECT, and DBS

Suicide Risk Mitigation Strategies: Embracing Technology and Enhancing Environmental Safety
Rosana Steavenson, Pharm.D., BCPS, BCPP
Program Manager
Mental Health Clinical Pharmacy Programs
South Texas Veterans Health Care System
- Examine the ethical evolution from focusing on suicide risk management systems to enhancing suicide risk mitigation strategies
- Discuss available technology to enhance suicide safety planning and protective factors
- Formulate techniques to improve environmental safety including limiting access to lethal means

Standing the Test of Time: What can we do for our Aging Population?
Rajesh T. Tampi, M.D., M.S., D.F.A.P.A.
Professor of Psychiatry
Case Western Reserve University School of Medicine
Associate Clinical Professor of Psychiatry, Yale School of Medicine
President Elect, American Association for Geriatric Psychiatry
- Categorize the different clinically relevant etiologies of impaired cognition in the elderly
- Distinguish between reversible and non-reversible target symptoms associated with cognition declines
- Explore current and potential best practice approaches for patients with potentially reversible cognitive impairment

ADHD Management Across the Ages
Steven R. Pliszka, M.D.
Dielmann Distinguished Professor and Chair
Department of Psychiatry
The University of Texas Health San Antonio
- Distinguish clinical features, diagnosis, and clinical monitoring tools for best-practice treatment of ADHD in child, adolescent, adult, and aged populations
- Appraise the current understanding of the efficacy and safety of ADHD treatments, workup, and the impact of comorbid disease states across the age spectrum
- Compare the current and near-horizon ADHD treatments (psychotherapy, nutritional, pharmacotherapy, and “video games”) with regard to mechanism of action, duration of activity, adverse effects, and cost

Current and Future Treatments for Alzheimer’s Disease and other Dementias
Sudha Seshadri, M.D.
Founding Director
Glenn Biggs Institute for Alzheimer’s & Neurodegenerative Diseases
The University of Texas Health San Antonio
- Review new insights into the pathophysiology of Alzheimer’s Disease and other dementias
- Summarize the current guideline recommendations for symptomatic treatment of Alzheimer’s Disease and other dementias
- Compare the impact of symptomatic versus disease-modifying treatments for dementia
- Explore novel disease-modifying treatments for Alzheimer’s disease and other dementias

The Growing Rate of Mental Illness in Adolescents and Young Adults
Hani Talebi, Ph.D., LSSP
Director, Pediatric Psychology
Texas Child Study Center, Dell Children’s Medical Center
Assistant Professor, Dept of Psychiatry and Behavioral Sciences
The University of Texas at Austin Dell School of Medicine
Rosni L. Koli, MD
Medical Director, Pediatric Mental Health
Dell Children’s Medical Center
Assistant Professor, Department of Psychiatry
The University of Texas at Austin Dell School of Medicine
- Summarize the incidence, prevalence, and recent changes in the rates and types of mental illness reported in adolescents and young adults
- Theorize about the causes and supporting evidence that have been proposed to explain the rise in mental illness in adolescents and young adults
- Develop recommendations on how to effectively screen adolescents and young adults in various clinical settings
## ON-DEMAND SESSIONS – Continued

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Presenters</th>
<th>Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.00</td>
<td>Essential Principles and Practices for Evidence-based Pharmacist</td>
<td>Peter S. Jensen, M.D.&lt;br&gt;Board Chair and Founder&lt;br&gt;REACH Institute, NY, NY&lt;br&gt;Adjunct Professor of Psychiatry&lt;br&gt;University of Arkansas for Medical Sciences</td>
<td>Discuss the key principles in performing evidence-based assessment and diagnosis of children &amp; adolescents with behavioral, emotional, and/or developmental problems. Describe the role of what constitutes “evidence-based prescribing” of psychotropic agents to children &amp; adolescents with psychiatric disorders. Apply evidence-based assessment, diagnosis, treatment planning, and service delivery to specific real-world clinical cases of child/adolescent psychiatric disorders.</td>
</tr>
<tr>
<td>1.00</td>
<td>Cultural Humility in Healthcare</td>
<td>Skyller Walkes, Ph.D.&lt;br&gt;Assistant Dean of Diversity and Inclusion&lt;br&gt;Assistant Professor of Instruction, Pharmacy Practice&lt;br&gt;The University of Texas at Austin College of Pharmacy&lt;br&gt;Glen Baumgart, Ph.D.&lt;br&gt;Director of Continuing Education&lt;br&gt;The University of Texas at Austin College of Pharmacy</td>
<td>Describe recent racial related protests, Black Lives Matter movement, and the meaning behind systematic racism. Discuss ethical issues related to race and the impact on healthcare for patients and healthcare professionals. Discuss action steps healthcare professionals may take to improve practice for themselves, their teams, and their patients.</td>
</tr>
<tr>
<td>1.00</td>
<td>The Psychological Impact of COVID-19 on Healthcare Professionals: Maintaining Ethical Practice</td>
<td>Victoria Latifses, Ph.D.&lt;br&gt;Director of Psychology, Austin State Hospital&lt;br&gt;Adjunct Faculty, St. Edward’s University &amp; Walden University</td>
<td>Describe the differences and similarities between compassion fatigue, vicarious trauma, moral distress and burnout in healthcare professionals. Explain 2 ethical practice considerations that are among the most commonly identified stressors for healthcare professionals during the COVID-19 pandemic. Identify 3 stress-relief strategies to alleviate psychological and emotional stress and improve mental well-being.</td>
</tr>
<tr>
<td>1.00</td>
<td>Unconscious Bias: Are we Treating All Patients Fairly and Equitably?</td>
<td>René Salazar, MD&lt;br&gt;Assistant Dean for Diversity&lt;br&gt;Professor of Medical Education&lt;br&gt;The University of Texas Dell School of Medicine</td>
<td>Describe unconscious bias. Recognize the impact of unconscious bias on healthcare delivery. Describe several strategies to mitigate the impact of unconscious bias on healthcare disparities.</td>
</tr>
<tr>
<td>1.00</td>
<td>Communicating with Patients about the Prescription Monitoring Program</td>
<td>Marc Fleming, PhD, MPH, RPh&lt;br&gt;Associate Professor and Chair, Department of Pharmacotherapy&lt;br&gt;University of North Texas System College of Pharmacy&lt;br&gt;Billy T. Table, Ph.D.&lt;br&gt;Research Fellow, Population Health&lt;br&gt;The University of Texas at Austin Dell School of Medicine</td>
<td>Discuss the impact of mandated PMP use. Debate pain management in the age of PMP and monitoring of morphine milligram equivalents MMEs. Assess healthcare professionals’ communication with patients concerning controlled substance prescriptions.</td>
</tr>
<tr>
<td>1.25</td>
<td>Opioid Use Disorder in the COVID Era</td>
<td>Lucas Hill, Pharm.D., BCPS, BCACP&lt;br&gt;Clinical Assistant Professor&lt;br&gt;The University of Texas at Austin College of Pharmacy</td>
<td>Describe best practices for opioid overdose prevention. Compare FDA-approved medications for opioid use disorder. Discuss current controversies and ethical issues in opioid use disorder treatment in the COVID 19 era.</td>
</tr>
</tbody>
</table>